#hepatocellular carcinoma

People with advanced fibrosis—not just cirrhosis—were at greater risk for hepatocellular carcinoma.

People treated with direct-acting antivirals had a lower risk for liver failure and liver cancer as well as much lower mortality.

Experts predict that more than a million people could die from liver cancer worldwide in 2040.

People who achieved SVR two or more years ago were less likely to develop hepatocellular carcinoma than those cured more recently.

People with hepatocellular carcinoma had improved survival after the advent of direct-acting antiviral therapy.

However, people with liver cirrhosis remain at risk and should continue screening even after being cured.

“I’m glad to go to bat for the One Liver to Love initiative to encourage others to be proactive,” says Latino legend Bernie Williams.

The risk of HCC fell further as cumulative antihistamine use rose in people with HBV, HCV or both.

Liver cancer is now less likely to be caused by hepatitis B or C, but more likely to be caused by fatty liver disease or alcohol.

More than a third of hepatocellular carcinoma cases among Medicare recipients were due to fatty liver disease.

Cases of the most common type of liver cancer, hepatocellular carcinoma, are on the rise.

Over the next two decades, obesity-linked NASH will lead to more deaths and high cost in the United States.

Less than 10% of people with cirrhosis were regularly monitored for liver cancer.

From 1995 to 2016, hepatocellular carcinoma incidence in rural populations climbed by 218%.

From 1992 to 2018, liver cancer cases related to hepatitis C fell in Japan.

Use of cholesterol-lowering medications was also associated with reduced mortality from liver cancer and other causes.